Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
By J. Macdonald, S. Smalley, J. Benedetti, S. Hundahl, N. C. Estes, G. Stemmermann, D. Haller, J. Ajani, L. Gunderson, J. Jessup and 1 more. New England Journal of Medicine, 2001
2,162 citations recorded by the source corpus.
Subfields: Gastroenterology, Pulmonary and Respiratory Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/7c6f17633d8be74ea5fb7a9fe18cffbafdb1a0cf
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Gastroenterology
In Pulmonary and Respiratory Medicine
In Surgery
Citations in the corpus
- Gastric Adenocarcinoma: Review and Considerations for Future Directions (2005, neutral): “Furthermore, although the surgical protocol recommended an extensive lymph node resection, less than 10% of patients received a formal D2 dissection, whereas 54% underwent a D0 dissection.(14) The authors conclude the greatest benefit of chemoradiotherapy may be in high-risk patients treated with in”
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. (2008, background): “The survival rate of patients with advanced resectable gastric or gastroesophageal junction (GEJ) cancers, however, remains poor despite new treatment strategies, such as perioperative chemotherapy [4] or adjuvant chemoradiation [5].”
- Japanese gastric cancer treatment guidelines 2010 (ver. 3) (2011, background): “In the West, both postoperative adjuvant chemoradiation [22] and perioperative chemotherapy [23] were shown to be superior to treatment with surgery alone in large-scale randomized trials.”